RWE Publications - Solid Tumor
Real-World PSA Response and Overall Survival Among Men with mCSPC Receiving Apalutamide Versus Darolutamide (Both Without Docetaxel) in the US
Bilen, M.A., Brown, G., Singhal, M. et al. Real-World PSA Response and Overall Survival Among Men with mCSPC Receiving Apalutamide Versus Darolutamide (Both Without Docetaxel) in the US. Adv Ther (2026).
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.